[Posterior reversible encephalopathy syndrome during nilotinib treatment for chronic myeloid leukemia].

• DOI: 10.11406/rinketsu.64.1514
• Publication Date: 2023-01-01
• Authors: Daisuke Kudo; Hiroshi Suzuki; Naomi Abe; Risen Hirai; Akira Tanimura; Masataka Takeshita; Akiyoshi Miwa

Here we present the case of a 50-year-old woman with chronic myeloid leukemia who received nilotinib as initial treatment. After about 2 years therapy, she developed headache, blurred vision, impaired consciousness, and marked hypertension. Posterior reversible encephalopathy syndrome (PRES) was diagnosed, strongly suspected to be vascular adverse event caused by nilotinib. Nilotinib withheld patient treated antihypertensive drugs under ventilator management. Her symptoms resolved quickly. The most likely cause PRES is systemic arterial hypertension endothelial dysfunction due direct injury leading at level blood-brain barrier, along resultant vasogenic edema. has been reported some tyrosine kinase inhibitors, but this first during